NICOLE BROWN: Open Payments
NPI 1518531227 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,497 in 66 payments from 11 companies in 2025. Trend: 2023 $1,839 · 2024 $2,317 · 2025 $2,497
Food & beverage: $2,491Education: $5
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 12 | $547 |
| Janssen Pharmaceuticals, Inc | 12 | $453 |
| Teva Pharmaceuticals USA, Inc. | 13 | $403 |
| Otsuka America Pharmaceutical, Inc. | 6 | $311 |
| Neurocrine BioSciences, Inc. | 7 | $232 |
| ABBVIE INC. | 8 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| E.R. Squibb & Sons, L.L.C. | 1 | $116 |
| Lundbeck LLC | 4 | $99 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
Products named: INVEGA SUSTENNA, UZEDY, INGREZZA, LYBALVI, ARISTADA, REXULTI, VRAYLAR, SPRAVATO.
Industry payments across OK — which companies pay providers there.
